BTIG Research assumed coverage on shares of NRx Pharmaceuticals (NASDAQ:NRXP – Free Report) in a research report released on Wednesday morning, MarketBeat reports. The brokerage issued a buy rating ...

As of April 2, 2025, the average one-year price target for NRx Pharmaceuticals is $32.30/share. The forecasts range from a low of $19.19 to a high of $47.25. The average price target represents an ...

NRx Pharmaceuticals has a twelve month low of $1.10 and a twelve month high of $6.01. The stock has a market capitalization of $34.68 million, a PE ratio of -0.96 and a beta of 1.22.

MIAMI - HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), currently valued at $35.18 million, has... ByInvesting.com • 24 Mar 2025 NRx Pharmaceuticals and HOPE ...

MIAMI, March 31, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc ...

Hope Therapeutics, an interventional psychiatry network wholly owned by NRx Pharmaceuticals (NRXP), announced signing of a definitive agreement ...

MIAMI - HOPE Therapeutics, Inc., a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP), has announced the signing of a definitive agreement to acquire Dura Medical, a provider of precision ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Shares of NRx Pharmaceuticals, Inc. (NRXP) have been struggling lately and have lost 5.1% over the past week. However, a hammer chart pattern was formed in its last trading session, which could ...